MARKET

PHAR

PHAR

Pharming Group N.V.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.70
-0.01
-0.14%
Closed 16:00 09/17 EDT
OPEN
9.70
PREV CLOSE
9.71
HIGH
9.70
LOW
9.61
VOLUME
424
TURNOVER
--
52 WEEK HIGH
21.99
52 WEEK LOW
9.61
MARKET CAP
626.74M
P/E (TTM)
198.77
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13)
Benzinga · 3d ago
BRIEF-Pharming Group Announces Results From Clinical Trials For Treatment Of Covid-19 With Ruconest
reuters.com · 4d ago
Pharming announces results from clinical trials for the treatment of COVID-19 with RUCONEST®
Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/NASDAQ: PHAR) announces the topline results from two randomized, open label, controlled, pilot clinical trials of patients hospitalized with COVID-19 treated with RUCONEST® (recom...
PR Newswire · 4d ago
JW Asset Management, LLC Buys Pharming Group, AdvisorShares Pure US Cannabis ETF, Medicus ...
GuruFocus News · 08/20 19:38
The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17)
Benzinga · 08/10 18:42
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9)
Benzinga · 08/10 11:55
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5)
Benzinga · 08/06 11:42
Pharming Group reports financial results for the first half of 2021
Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/NASDAQ: PHAR) presents its preliminary (unaudited) financial report for the first six months of 2021 ended June 30, 2021.
PR Newswire · 08/05 05:00
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PHAR. Analyze the recent business situations of Pharming Group N.V. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Webull offers kinds of Pharming Group N.V. stock information, including NASDAQ:PHAR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHAR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PHAR stock methods without spending real money on the virtual paper trading platform.